Kabra Drugs has emerged as a standout multibagger penny stock, delivering remarkable returns to long-term investors. According to reports from Live Mint, the stock's journey from ₹0.65 in February 2019 to ₹32 on BSE represents a 4960% return over seven years. An investment of ₹1 lakh made six years ago would have grown significantly to ₹50 lakh in the current period, demonstrating the stock's wealth-creating potential for patient investors.
The stock has demonstrated impressive momentum across multiple timeframes despite challenging market conditions. As reported by Live Mint, Kabra Drugs has gained 209% in a year, significantly outperforming the BSE Sensex's modest 10% rise during the same period. The stock has also delivered 65% returns in six months and 17% in a month, showcasing consistent short-term performance alongside its long-term wealth creation capabilities.
The company has achieved a remarkable financial turnaround, reporting strong quarterly results for Q3 FY26. According to PTI reports cited by Live Mint, Kabra Drugs posted a 578% year-on-year surge in net profit to ₹2.56 crore for the December quarter, compared to a loss of ₹53.69 lakh in the same period last year. The company's revenue reached ₹30.42 crore, reflecting a 53.9% jump from ₹19.76 crore recorded in the September 2025 quarter, with a significant turnaround from zero revenue reported in December 2024.
The company has undertaken several strategic initiatives to enhance its market presence and operational capabilities. As reported by Live Mint, Kabra Drugs entered into an agreement with MR Franchise to onboard 200 channel partners across the country, significantly expanding its distribution network and market footprint. Additionally, the company board approved key updates on January 1, including acquisition of Vassmaan Automotive Pvt Ltd, name change, expansion of distribution network, and diversification of main objects to support future growth initiatives.
